Superficial fungal infections caused by dermatophytes and yeasts are among the commonest cutaneous diseases. Fortunately, in the United Kingdom systemic fungal infections are rare, although their incidence in recent years has been increased by opportunistic infection in immunosuppressed patients. Despite this increase in systemic infections the development of effective antifungal drugs has lagged well behind that of antibiotics, at least in part because fewer differences in cell type exist between the eukaryotic fungal pathogen and host than between the prokaryotic bacterial pathogen and host. Until 1970 there were a few antifungal drugs, which had certain limitations including toxicity, narrow spectrum of activity, parenteral administration, and commonly a failure to cure. With the advent of the imidazole derivatives a major new class of antifungal drugs has emerged which combines low toxicity and versatility of administration with a wide spectrum of antifungal action against dermatophytes, yeasts, and dimorphic fungi.
lesions. Isoconazole (Travogyn) is given as a single dose vaginal tablet. Systemic absorption of these drugs from the skin or from the vagina is minimal. Side effects are uncommon (1-4%) consisting of minor irritation, burning, or itching at the site of application.
Intravenous administration
Intravenous administration of miconazole (Daktarin) produces therapeutic drug concentrations in bone, joint, lung, and oesophageal tissue. Intrathecal administration is necessary for meningeal and cerebral infections. The drug is rapidly metabolised in the liver and its excretion is unaffected by renal insufficiency. Side effects are uncommon; intestinal disturbance is the most frequent while pruritus, rash, fever, anaemia, and thrombocytosis occur rarely. Miconazole enhances the anticoagulant effect of warfarin.
Oral administration
Therapeutic concentrations of ketoconazole (Nizoral) are achieved one to two hours after a 200 mg oral dose. As it is a dibasic drug optimal absorption occurs in conditions of increased acidity such as exist when the drug is taken with food. Conversely, when it is taken with an antacid or the H, receptor antagonist cimetidine blood concentrations of ketoconazole may be appreciably reduced. It is widely distributed in the body tissues with penetration of saliva, urine, sebum, and breast milk, but intracerebral concentrations are too low to be therapeutic. In the plasma it is protein bound, primarily to albumin, and is extensively metabolised in the liver. Excretion is by biliary and faecal routes. Gastrointestinal irritation occurs in 500 of patients and less frequent side effects include nausea, headaches, pruritus, and rarely gynaecomastia. Hepatotoxicity has been reported with asymptomatic transitory increases in enzyme activity as well as symptomatic reactions of hepatocellular and cholestatic type. These reactions are rare with an incidence of less than 1/10 000 patients treated. The drug is contraindicated in pregnancy. Ketoconazole (200 mg vaccine has been used successfully in children whose leukaemia is in complete remission after chemotherapy. Amantadine (Symmetrel) inhibits the penetration of influenza A virus into the host cell. It has some value as a prophylactic agent in contacts but early trials suggest that it does not help symptomatic patients. Rimantadine is a derivative that has been studied in the Soviet Union; initial results show that it may be useful in treating symptomatic influenza A, and this has prompted a re-evaluation of amantadine. Neither drug is active against influenza B.
All other antiviral drugs inhibit nucleic acid synthesis. Acyclovir has recently been marketed in the United Kingdom. There are several other new drugs, however, that are either marketed abroad (Trifluridine) or have been used in clinical trials (bromovinyl deoxyuridine, ribavirin) and require brief discussion. All of the presently available agents act by inhibiting viral DNA polymerase and are active against only the herpes group of viruses (herpes simplex, varicella zoster, cytomegalovirus) and the hepatitis B virus, which is also a DNA virus. Idoxuridine (Herpid), an iodinated derivative of thymidine, is cytotoxic and mutagenic when given systemically. It is only used for the topical treatment of shingles and herpes simplex keratitis. Trifluridine, also a halogenated derivative of thymidine, is more effective than idoxuridine for the treatment of superficial herpetic keratitis and causes less local tissue reaction. Neither drug is effective against deep infections. Trifluridine is not available in the United Kingdom at present. Bromovinyl deoxyuridine is another related compound which is activated by virus specific enzymes and may be given systemically. Unfortunately, it does not cross the blood-brain barrier so it cannot be used to treat herpes encephalitis and it does not work against herpes virus type 2, the cause of genital herpes. Its clinical application is therefore likely to be limited. ACYCLOVIR Acyclovir (Zovirax) is inactive until phosphorylated by a herpes specific enzyme (thymidine kinase). The triphosphate that is formed inhibits DNA polymerase. In vitro it is the most active drug against herpes viruses and is far more active than vidarabine (adenine arabinoside, Vira-A), the only other systemic antiviral available. Viral activity is measured as the concentration that inactivates at least 50% of the virus (ED50). Acyclovir is commercially available as a topical ointment, in tablet form, and as an intravenous injection. The ointment should be used only for ophthalmic infections. Absorption of the oral preparation is poor (about 20%). The resultant peak blood concentrations will reliably exceed the ED50 of herpes simplex but not of the other herpes viruses. On the other hand, the peak concentrations obtained after intravenous administration of acyclovir exceed the ED50 of varicella zoster, Epstein-Barr virus, and hepatitis B virus but do not exceed the ED50 of all cytomegalovirus strains. The usual oral dosage in the treatment of herpes simplex is 200 mg five times daily for five days. Acyclovir is not appreciably plasma protein bound and is excreted unchanged in the urine; the dose must be reduced in severe renal failure-for example, 200 mg orally every 12 hours. To date few adverse effects have been encountered. Acyclovir may have a local irritant effect-for example, transient stinging after ophthalmic use or skin inflammation if extravasation with intravenous administration occurs. There have been occasional reports of increased liver related enzymes and rashes after intravenous use but the only consistent toxic effect is a slight increase in blood urea concentration, which is probably due to drug crystals in the urine. This can usually be avoided by a slow infusion.
Acyclovir resistant strains of herpes simplex and varicella zoster already exist. The commonest mechanism of resistance is a failure of the virus to produce thymidine kinase, the enzyme that activates acyclovir. These strains may be sensitive to vidarabine but strains resistant to acyclovir because of defective DNA polymerases are usually resistant to vidarabine.
Clinical applications of acyclovir
Herpes virus infections occur in patients with normal or impaired immunity but the clinical problems of the two patient groups are entirely different. In patients with normal immunity the infections are largely self limiting and the goals of antiviral treatment are the reduction of morbidity and the prevention of reinfection. In contrast, herpes infections in immunocompromised patients are life threatening. There is no doubt that acyclovir is a major advance in antiviral treatment; it is also an expensive drug that should not be used indiscriminately because of the danger of encouraging resistant strains.
Mucocutaneous herpes simplex-In the normal host acyclovir cream merely reduces the duration of viral shedding without producing any clinical benefit or preventing reinfections. In contrast, intravenous acyclovir reduces the morbidity and mortality of mucocutaneous herpes simplex in the immunocompromised host. Infections are, however, prolonged even with treatment and this may interfere with other aspects of the patient's treatment such as cytotoxic therapy. Prophylactic oral acyclovir reduces the frequency of herpes infection in these patients, but it remains to be seen whether this will produce resistant infections.
Ophthalmic herpes simplex-Acyclovir ointment has been shown to be superior to idoxuridine and trifluridine in the rate of healing and in preventing complications. The results of comparative trials with vidarabine are conflicting but the largest trial has shown that acyclovir is superior.
Genital herpes simplex-Intravenous and oral acyclovir appreciably reduce the duration of symptoms but neither affects reinfection. The quickest way to get a bad reference for future jobs is to alienate others by inconsiderate behaviour. Your watchword must be "You judge yourself by your intentions and others by their actions." You know that you are a nice chap who never intends to hurt or harm anyone else, but often you are misunderstood. If you stop and think about it you will see that certain people seem more often to be misunderstood and resented than others. You know who they are, you do dislike their behaviour, and you know that it is their fault. Make sure that you too do not unwittingly behave badly and acquire a poor reputation.
Others judge you by your actions, which include what you do, what you say, and what you convey by your attitudes. When you move into a new job you are at first in an alien environment. You are the invader of a more or less cohesive in'-group. They will be wary and watchful of you, even though they are also welcoming. They want to know whether you will fit in or not. They cannot know this except over time and seeing how you behave, so you need to be a little circumspect. Do As soon as you have been appointed you will probably be handed over to one of the administrative staff who will show you round, perhaps to see the living accommodation and to arrange when you will start and at what salary. These may also be many other details to talk about. Administration is essential: do not be contemptuous of those who do it, for they are concerned to see that you are inducted as painlessly as possible into your new job. It is better for them if you are happy in their institution, so seek their cooperation. They are not your inferiors to do your bidding. They will help willingly if approached in the right way. You do not at first know where in the hierarchy this particular administrator sits, but his or her impressions of you will certainly be handed on to others and may reach the chief administrator and ultimately the consultant for whom you work. It is not a question of whether the impressions of you are correct or not. Frequently first ones are not, but they form the foundations of your reputation. Therefore be courteous.
Do not turn up for the job at the last minute. If your post begins on the 10th be there on the 9th. Unless you have made sure, the job may begin at 9 am and not the evening of the first day. A room may have to be prepared for you and a meal. Tell the administration in writing just what you intend to do, well in advance-telephoning is not enough as a call is quickly and easily forgotten unless a note is made. Too few people do this. A letter on the other hand is a constant reminder on which action must be taken, and it does not then matter if the recipient falls ill or goes on holiday or is just too busy to take much note of a phone call. Moreover, the copy of the letter which you send is a reminder to you of just what you have said you will do. You must stick to this and not vary it except for the most cogent reasons. If you do change your mind apologise to the persons you have inconvenienced, preferably before you have inconvenienced them.
A quality most revered by all, but especially chiefs, is reliability. You will appreciate it in others too. If you are asked to do something do it. If you are expected in a certain place at a certain time be there. This is especially necessary if you are to meet your chief in the operating theatre or on a ward round.
